Positive feedback loop between PI3K-Akt-mTORC1 signaling and the lipogenic pathway boosts Akt signaling: Induction of the lipogenic pathway by a melanoma antigen

Cancer Research

Volumn 71, Issue 14, 2011, Pages 4989-4997

  Yamauchi, Yoshio ^a   Furukawa, Keiko ^b   Hamamura, Kazunori ^a   Furukawa, Koichi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHUBU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GANGLIOSIDE GD3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MAMMALIAN TARGET OF RAPAMYCIN; MELANOMA ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID RAFT; LIPOGENESIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; FEEDBACK, PHYSIOLOGICAL; FEMALE; GANGLIOSIDES; HUMANS; LIPOGENESIS; MELANOMA; MEMBRANE MICRODOMAINS; MICE; MICE, INBRED BALB C; MUTATION; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 79960385476     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4108     Document Type: Article

References (50)

1. Hsu P, Sabatini D. Cancer cell metabolism: Warburg and beyond. Cell 2008;134:703-7.
2. Vander Heiden M, Cantley L, Thompson C. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
3. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-82. (Pubitemid 351766797)
4. Menendez J, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-77. (Pubitemid 47469806)
5. Katz M. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2005;2:82-9. (Pubitemid 40790141)
6. Demierre M, Higgins P, Gruber S, Hawk E, Lippman S. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42. (Pubitemid 41766782)
7. Horton J, Goldstein J, Brown M. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31. (Pubitemid 34496588)
8. Goldstein J, DeBose-Boyd R, Brown M. Protein sensors for membrane sterols. Cell 2006;124:35-46.
9. Horton J, Shah N, Warrington J, Anderson N, Park S, Brown M, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 2003;100:12027-32. (Pubitemid 37271509)
10. Krycer J, Sharpe L, Luu W, Brown A. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab 2010;21:268-76.
11. Guo D, Prins R, Dang J, Kuga D, Iwanami A, Soto H, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2009;2:ra82.
12. Ettinger S, Sobel R, Whitmore T, Akbari M, Bradley D, Gleave M, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004;64:2212-21. (Pubitemid 38339475)
13. Regina Todeschini A, Hakomori S. Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta 2008;1780:421-33. (Pubitemid 351381254)
14. Thampoe I, Furukawa K, Vellvé E, Lloyd K. Sialyltransferase levels and ganglioside expression in melanoma and other cultured human cancer cells. Cancer Res 1989;49:6258-64. (Pubitemid 20000919)
15. Pukel C, Lloyd K, Travassos L, Dippold W, Oettgen H, Old L. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med 1982;155:1133-47. (Pubitemid 12142729)
16. Merritt W, Casper J, Lauer S, Reaman G. Expression of GD3 ganglioside in childhood T-cell lymphoblastic malignancies. Cancer Res 1987;47:1724-30. (Pubitemid 17044511)
17. Siddiqui B, Buehler J, DeGregorio M, Macher B. Differential expression of ganglioside GD3 by human leukocytes and leukemia cells. Cancer Res 1984;44:5262-5. (Pubitemid 15204498)
18. Okada M, Furukawa K, Yamashiro S, Yamada Y, Haraguchi M, Horibe K, et al. High expression of ganglioside alpha-2,8-sialyltransferase (GD3 synthase) gene in adult T-cell leukemia cells unrelated to the gene expression of human T-lymphotropic virus type I. Cancer Res 1996;56:2844-8.
19. Hamamura K, Furukawa K, Hayashi T, Hattori T, Nakano J, Nakashima H, et al. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc Natl Acad Sci U S A 2005;102:11041-6. (Pubitemid 41105989)
20. Ohkawa Y, Miyazaki S, Hamamura K, Kambe M, Miyata M, Tajima O, et al. Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains. J Biol Chem 2010;285:27213-23.
21. Fukumoto S, Mutoh T, Hasegawa T, Miyazaki H, Okada M, Goto G, et al. GD3 synthase gene expression in PC12 cells results in the continuous activation of TrkA and ERK1/2 and enhanced proliferation. J Biol Chem 2000;275:5832-8. (Pubitemid 30115229)
22. Zeng G, Gao L, Yu R. Reduced cell migration, tumor growth and experimental metastasis of rat F-11 cells whose expression of GD3-synthase is suppressed. Int J Cancer 2000;88:53-7.
23. Nakashima H, Hamamura K, Houjou T, Taguchi R, Yamamoto N, Mitsudo K, et al. Overexpression of caveolin-1 in a human melanoma cell line results in dispersion of ganglioside GD3 from lipid rafts and alteration of leading edges, leading to attenuation of malignant properties. Cancer Sci 2007;98:512-20. (Pubitemid 46562741)
24. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387:569-72. (Pubitemid 27248754)
25. Nakano J, Raj B, Asagami C, Lloyd K. Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic characteristics. J Invest Dermatol 1996;107:543-8. (Pubitemid 26338576)
26. Yamauchi Y, Reid P, Sperry J, Furukawa K, Takeya M, Chang C, et al. Plasma membrane rafts complete cholesterol synthesis by participating in retrograde movement of precursor sterols. J Biol Chem 2007;282:34994-5004. (Pubitemid 350232452)
27. Yamauchi Y, Hayashi M, Abe-Dohmae S, Yokoyama S. Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J Biol Chem 2003;278:47890-7. (Pubitemid 37523237)
28. Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
29. Tsao H, Goel V, Wu H, Yang G, Haluska F. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122:337-41. (Pubitemid 38281053)
30. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 2010;22:169-76.
31. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003;107:873-7. (Pubitemid 37429826)
32. Gao X, Zhang J. Spatiotemporal analysis of differential Akt regulation in plasma membrane microdomains. Mol Biol Cell 2008;19:4366-73.
33. Lasserre R, Guo X, Conchonaud F, Hamon Y, Hawchar O, Bernard A, et al. Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol 2008;4:538-47.
34. Fedida-Metula S, Elhyany S, Tsory S, Segal S, Hershfinkel M, Sekler I, et al. Targeting lipid rafts inhibits protein kinase B by disrupting calcium homeostasis and attenuates malignant properties of melanoma cells. Carcinogenesis 2008;29:1546-54.
35. Adam R, Mukhopadhyay N, Kim J, Di Vizio D, Cinar B, Boucher K, et al. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res 2007;67:6238-46. (Pubitemid 47037505)
36. Zhuang L, Kim J, Adam R, Solomon K, Freeman M. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959-68. (Pubitemid 40489400)
37. Pitroda S, Khodarev N, Beckett M, Kufe D, Weichselbaum R. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A 2009;106:5837-41.
38. Chang T, Chang C, Ohgami N, Yamauchi Y. Cholesterol sensing, trafficking, and esterification. Annu Rev Cell Dev Biol 2006;22:129-57.
39. Radhakrishnan A, Goldstein J, McDonald J, Brown M. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab 2008;8:512-21.
40. Porstmann T, Griffiths B, Chung Y, Delpuech O, Griffiths J, Downward J, et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005;24:6465-81. (Pubitemid 41486630)
41. Du X, Kristiana I, Wong J, Brown A. Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: a link between a key cell proliferative pathway and membrane synthesis. Mol Biol Cell 2006;17:2735-45. (Pubitemid 43825509)
42. Porstmann T, Santos C, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 2008;8:224-36.
43. Li S, Brown M, Goldstein J. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A 2010;107:3441-6.
44. Düvel K, Yecies J, Menon S, Raman P, Lipovsky A, Souza A, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010;39:171-83.
45. Gong Y, Lee J, Lee P, Goldstein J, Brown M, Ye J. Sterol-regulated ubiquitination and degradation of Insig-1 creates a convergent mechanism for feedback control of cholesterol synthesis and uptake. Cell Metab 2006;3:15-24.
46. Yellaturu C, Deng X, Cagen L, Wilcox H, Mansbach Cn, Siddiqi S, et al. Insulin enhances post-translational processing of nascent SREBP-1c by promoting its phosphorylation and association with COPII vesicles. J Biol Chem 2009;284:7518-32.
47. Gil G, Faust J, Chin D, Goldstein J, Brown M. Membrane-bound domain of HMG CoA reductase is required for sterol-enhanced degradation of the enzyme. Cell 1985;41:249-58. (Pubitemid 15068442)
48. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein L, et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 2004;5:253-61. (Pubitemid 38402117)
49. Wang H, Altomare D, Skele K, Poulikakos P, Kuhajda F, Di Cristofano A, et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005;24:3574-82. (Pubitemid 40756227)
50. Karbowniczek M, Spittle C, Morrison T, Wu H, Henske E. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008;128:980-7. (Pubitemid 351374287)